Kazuharu Kai

Kazuharu Kai, MD, PhD, is a Senior Medical Director and Clinical Lead at Allogene Therapeutics since August 2021. Prior experience includes roles as Senior Medical Director at Nektar Therapeutics, Medical Director at Karyopharm Therapeutics Inc., and Clinical Development Lead/Medical Monitor at Bristol-Myers Squibb. Kazuharu Kai has also served as a Research Instructor and Postdoctoral Fellow at MD Anderson Cancer Center, and held various research and clinical positions at Keio University, Kumamoto University, and Kumamoto City Hospital in Japan. Kazuharu Kai earned a Doctor of Medicine degree from Kumamoto University in 1999 and a Doctor of Philosophy in Oncology and Cancer Biology from the same institution in 2009.